120 related articles for article (PubMed ID: 8639381)
21. Cancer drugs in pipeline span wide spectrum.
McCann J
J Natl Cancer Inst; 2001 Mar; 93(6):424-6. PubMed ID: 11259465
[No Abstract] [Full Text] [Related]
22. Accelerated approval regulations may need overhaul, panel suggests.
Finkelstein JB
J Natl Cancer Inst; 2005 Dec; 97(24):1802-4. PubMed ID: 16368938
[No Abstract] [Full Text] [Related]
23. TLK-286.
Verschraegen CF; Smith HO; Lee FC; Cathcart C; Norenberg JP
IDrugs; 2004 Aug; 7(8):771-81. PubMed ID: 15334311
[TBL] [Abstract][Full Text] [Related]
24. Incorporating novel treatment strategies into conventional therapy.
Estey EH
Clin Adv Hematol Oncol; 2009 Jun; 7(6):4-7. PubMed ID: 19645129
[No Abstract] [Full Text] [Related]
25. New, expanded, and modified use of approved antineoplastic agents in ovarian cancer.
Markman M
Oncologist; 2007 Feb; 12(2):186-90. PubMed ID: 17296814
[TBL] [Abstract][Full Text] [Related]
26. Can single-patient investigational new drug studies hurry slow trains to the fast track?
Chenoweth D
Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
[TBL] [Abstract][Full Text] [Related]
27. American Association for Cancer Research 98th Annual Meeting. Anticancer agents - Part I.
Kneller S
IDrugs; 2007 Jun; 10(6):356-8. PubMed ID: 17641993
[No Abstract] [Full Text] [Related]
28. [New therapeutic strategies in oncology].
Bohuon C
Ann Pharm Fr; 2010 Jul; 68(4):203-4. PubMed ID: 20637352
[No Abstract] [Full Text] [Related]
29. Platinum(IV) anticancer complexes.
Hall MD; Dolman RC; Hambley TW
Met Ions Biol Syst; 2004; 42():297-322. PubMed ID: 15206106
[No Abstract] [Full Text] [Related]
30. Slow start to phase 0 as researchers debate value.
Twombly R
J Natl Cancer Inst; 2006 Jun; 98(12):804-6. PubMed ID: 16788150
[No Abstract] [Full Text] [Related]
31. Lapatinib ditosylate GlaxoSmithKline.
Kim TE; Murren JR
IDrugs; 2003 Sep; 6(9):886-93. PubMed ID: 12964069
[TBL] [Abstract][Full Text] [Related]
32. 27th Annual JPMorgan Healthcare Conference--BioCryst and Emergent Biosolutions.
Croasdell G; Gale S
IDrugs; 2009 Mar; 12(3):149-51. PubMed ID: 19333891
[No Abstract] [Full Text] [Related]
33. The effect of cytoprotective agents in platinum anticancer therapy.
Jakupec MA; Galanski M; Keppler BK
Met Ions Biol Syst; 2004; 42():179-208. PubMed ID: 15206103
[No Abstract] [Full Text] [Related]
34. Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.
Muggia FM
Semin Oncol; 2004 Dec; 31(6 Suppl 14):17-24. PubMed ID: 15726530
[TBL] [Abstract][Full Text] [Related]
35. Antiangiogenic therapy at a crossroads: clinical trial results and future directions.
Ellis LM
J Clin Oncol; 2003 Dec; 21(23 Suppl):281s-283s. PubMed ID: 14645411
[No Abstract] [Full Text] [Related]
36. New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective.
Awada A; Mano M; Hendlisz A; Piccart M
Expert Rev Anticancer Ther; 2004 Feb; 4(1):53-60. PubMed ID: 14748657
[TBL] [Abstract][Full Text] [Related]
37. [Cytostatic drugs. 1: Platinum compounds, alkylating and intercalating cytostatic drugs].
Bauch HJ
Med Monatsschr Pharm; 1989 Jan; 12(1):8-20. PubMed ID: 2643766
[No Abstract] [Full Text] [Related]
38. Major contributions towards finding a cure for cancer through chemotherapy: a historical review.
Masood I; Kiani MH; Ahmad M; Masood MI; Sadaquat H
Tumori; 2016; 102(1):6-17. PubMed ID: 26350183
[TBL] [Abstract][Full Text] [Related]
39. Review of platinum anticancer compounds.
Gordon M; Hollander S
J Med; 1993; 24(4-5):209-65. PubMed ID: 8258739
[No Abstract] [Full Text] [Related]
40. Novel drugs--miscellaneous category.
Hosmer WD; Dubinett SM; Garon EB
J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S468-9. PubMed ID: 21102242
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
